1084. Comparison of Outcomes in Outpatient Parenteral Antimicrobial Therapy (OPAT) Patients Receiving Vancomycin versus Non-Vancomycin Anti-MRSA Therapy
Session: Poster Abstract Session: Clinical Practice Issues
Friday, October 6, 2017
Room: Poster Hall CD
  • Vanco vs NVAMT IDWeek 2017 Poster 09202017.pdf (233.3 kB)
  • Background:

    This evaluation set out to determine if vancomycin therapy was associated with higher rates of clinical failure compared to non-vancomycin anti-methicillin-resistant Staphylococcus aureus therapy (NVAMT) in outpatient parenteral antimicrobial therapy (OPAT).


    This was a retrospective, single center cohort study including patients who received ≥ 7 days of OPAT with vancomycin, ceftaroline, or daptomycin from 01/01/2009 through 03/31/2016 at the VA Saint Louis Healthcare System. The primary outcome was clinical failure, defined as a composite of acute kidney injury (AKI), creatinine phosphokinase elevations ≥ 500 units/L, adverse drug events necessitating a change in therapy, readmission due to recurrence of infection, or reinitiation of antibiotics after discontinuation. Secondary outcomes were the individual components of the composite primary outcome. Multivariate logistic regression was used to evaluate independent risk factors for clinical failure. Factors evaluated for inclusion in the multivariate model were age >65 at initiation, creatinine clearance >50 mL/min, length of therapy >28 days, concomitant antibiotic therapy, comorbid disease states, and vancomycin therapy.


    A total of 125 patients were included in the analysis – 72 receiving vancomycin and 53 receiving NVAMT. Baseline characteristics between groups were similar, except patients in the NVAMT group had a greater mean serum creatinine and a higher rate of CKD at baseline; 1.53 vs 1.23 (p=0.032) and 35.9% vs. 19.4% (p=0.04) respectively. Forty three percent (31/72) of patients receiving vancomycin achieved clinical failure compared to 54.7% (29/53) of NVAMT patients (p=0.197). Of the secondary outcomes analyzed, only readmission due to recurrence was significant between groups (vancomycin vs. NVAMT) – 13.8% vs. 30.2% (p=0.026). In the univariate model only the choice of vancomycin met pre-defined criteria (p<0.2) for inclusion in the multivariate model. In the multivariate analysis the choice of vancomycin was not found to be significant (0.71 (95% CI 0.33-1.52), p=0.37).


    Vancomycin was not associated with an increased risk of clinical failure when compared to NVAMT in patients receiving OPAT.

    Carolyn Stoneking, Pharm.D., Pharmacy, VA St. Louis Healthcare System, St. Louis, MO, Ryan P. Moenster, Pharm.D., FIDSA, Pharmacy Services, VA Saint Louis Health Care System, Saint Louis, MO and Travis W. Linneman, Pharm.D., Pharmacy Services/Medicine Specialty Care, St. Louis VA Medical Center - John Cochran Division, St. Louis, MO


    C. Stoneking, None

    R. P. Moenster, None

    T. W. Linneman, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.